Topic: Huntington's disease
Teva is riding high after a strong launch for Austedo. But is "tenfold" patient growth in one of its indications possible? Analysts aren't so sure.
In May 2017, Pope Francis met with a group of Huntington’s patients. Now, Roche's Genentech is backing a documentary about it.
Under pressure in generics, Teva could use some help from its specialty department, and the newly approved Huntington’s chorea med Austedo could bring just that.
Drugmakers like Teva are looking to bring back hydrogen as a possible delivery mechanism for drugs as the heavier element could slow the breakdown of compounds in the body and allow the patients to take medications on a less frequent basis.